Medical/Pharmaceuticals APAC News & Press Release Distribution

Medical/Pharmaceuticals

All
Global

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorpho...

2024-01-05 14:35 2354

Therabody, the Global Leader In Wellness Technology, Defends Against Recent Patent Infringement Lawsuit Filed by Hyperice

As the leading percussive patent owner and the driving force behind many of today's wellness innovations, Therabody will vigorously defend itself against the recent patent infringement lawsuit filed by Hyperice. LOS ANGELES, Jan. 5, 2024 /PRNewswire/ -- Therabody, the leader in tech wellness and...

2024-01-05 06:33 4645

Greenway Health Earns Frost & Sullivan's 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Products and Services that Enhance Health Providers and Patients Experiences

Greenway Health™ (Greenway®) offers groundbreaking client-centric electronic health record (EHR) and practice management software that streamline workflows and improve patient outcomes through a unique blend of in-depth insights and cutting-edge technology. SAN ANTONIO, Jan. 5, 2024 /PRNewswire/...

2024-01-05 04:30 3420

Greenway Health Earns Frost & Sullivan's 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Products and Services that Enhance Health Providers and Patients Experiences

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...

2024-01-05 00:19 4439

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the ...

2024-01-04 21:40 5325

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical study in advanced solid tumors - Avenzo also obtains an exclusive option to an additional preclinical program planned ...

2024-01-04 21:02 2607

Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia, Jan. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference inSan Francisco, CA (US). The pre...

2024-01-04 06:20 3035

Mr. Chong-Yoon Lim, Chairman of COREE Group emphasizes "Creative destruction and Healthcare 4.0" [New Year Message at X-Twitter SNS]

SEOUL, South Korea, Jan. 3, 2024 /PRNewswire/ -- Chong-Yoon Lim, Chairman of COREE group, President of Hanmi pharmaceutical company and Former Chairman of Korea Biotechnology Industry Organization (The largest shareholder group of Coree HK, Hanmi (KOSPI) and Dx&Vx (KOSDAQ), as well), highlighted ...

2024-01-03 22:00 3789

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

* Company announces development of novel ionizable lipids and stabilizing components * eTurna™ delivery platform expected to improve safety, reduce immunogenicity * Customizable platform can be optimized to treat variety of cells, tissues and organs * Platform can accommodate different rou...

2024-01-03 22:00 3423

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to anno...

2024-01-03 20:00 7282

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis...

2024-01-03 19:37 4366

Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independen...

2024-01-03 18:10 6744

Bangkok Dusit Medical Services strengthens partnership with CNN focusing on global health issues and solutions

HONG KONG, Jan. 3, 2024 /PRNewswire/ -- Bangkok Dusit Medical Services Public Company Limited (BDMS), the largest private healthcare network inThailand, is continuing its long-term partnership with CNN International Commercial (CNNIC) through the sponsorship ofVital Signs

2024-01-03 11:30 3653

Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China

* Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo * In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤ 6.5% and 35.2% achieved HbA1c< ...

2024-01-03 10:00 4229

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

NATICK, Mass., Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US andChina-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with A...

2024-01-02 22:00 3093

Novel Device Facilitates Successful No-Shave FUE Transplants for Long Hair with Ease

LOS ANGELES, Jan. 2, 2024 /PRNewswire/ -- A recent study published in the Clinical, Cosmetic and Investigational Dermatology journal reveals a groundbreaking advancement in hair transplantation, reports Dr U Hair and Skin Clinic. The research, titled "No-Shave Long Hair Follicular Unit Excision u...

2024-01-02 21:00 2770

Novel Device Facilitates Successful No-Shave FUE Transplants for Long Hair with Ease

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), recently announced that it has successfully obtained Humanitarian Use Device (HUD) designation from the US FDA and approval ...

2024-01-02 20:30 3556

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet --At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat content from baseline ...

2024-01-02 20:06 4692

Xinhua Silk Road: Xinhua-Yushu Wild Cordyceps Sinensis Price Index unveiled in Beijing

BEIJING, Jan. 2, 2024 /PRNewswire/ -- The Xinhua-Yushu Wild Cordyceps Sinensis Price Index was officially released on Dec. 27th inBeijing, capital of China, indicating the accelerated development of wild cordyceps sinensis industry towards a new stage of digital, information and modern mode.

2024-01-02 10:06 4239

Xinhua Silk Road: Xinhua-Yushu Wild Cordyceps Sinensis Price Index unveiled in Beijing

Demron by RST - Advanced Protection Against Today's Nuclear Threats

MIAMI, Jan. 2, 2024 /PRNewswire/ -- Radiation Shield Technologies (RST) proudly marks over two decades of innovation with Demron, a unique fabric designed to safeguard frontline personnel, including military, nuclear industry workers, emergency response teams, Hazmat Teams, firefighters, law enfo...

2024-01-02 08:00 3385

1 ... 201 202 203204205 206 207 ... 380